Venom Peptides, Polyphenols and Alkaloids: Are They the Next Antidiabetics That Will Preserve β-Cell Mass and Function in Type 2 Diabetes?

Cells. 2023 Mar 20;12(6):940. doi: 10.3390/cells12060940.

Abstract

Improvement of insulin secretion by pancreatic β-cells and preservation of their mass are the current challenges that future antidiabetic drugs should meet for achieving efficient and long-term glycemic control in patients with type 2 diabetes (T2D). The successful development of glucagon-like peptide 1 (GLP-1) analogues, derived from the saliva of a lizard from the Helodermatidae family, has provided the proof of concept that antidiabetic drugs directly targeting pancreatic β-cells can emerge from venomous animals. The literature reporting on the antidiabetic effects of medicinal plants suggests that they contain some promising active substances such as polyphenols and alkaloids, which could be active as insulin secretagogues and β-cell protectors. In this review, we discuss the potential of several polyphenols, alkaloids and venom peptides from snake, frogs, scorpions and cone snails. These molecules could contribute to the development of new efficient antidiabetic medicines targeting β-cells, which would tackle the progression of the disease.

Keywords: alkaloids; diabetes; insulin secretagogues; pancreatic beta cell; peptides; polyphenols; venom.

Publication types

  • Review

MeSH terms

  • Alkaloids* / pharmacology
  • Alkaloids* / therapeutic use
  • Animals
  • Diabetes Mellitus, Type 2* / drug therapy
  • Hypoglycemic Agents / chemistry
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use
  • Peptides / pharmacology
  • Polyphenols / pharmacology
  • Polyphenols / therapeutic use
  • Venoms / pharmacology
  • Venoms / therapeutic use

Substances

  • Hypoglycemic Agents
  • Polyphenols
  • Venoms
  • Peptides
  • Alkaloids

Grants and funding

This research received no external funding. The APC was covered by the full waiver from the journal.